Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Sun Pharmaceutical Industries Ltd banner

Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA

Watchlist Manager
Sun Pharmaceutical Industries Ltd Logo
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Watchlist
Price: 1 853 INR 0.98% Market Closed
Market Cap: ₹4.4T
Write Note Create Alert Ask AI

Wall St Price Targets

SUNPHARMA Price Targets Summary
Sun Pharmaceutical Industries Ltd

Wall Street analysts forecast SUNPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SUNPHARMA is 2 193 INR with a low forecast of 1 848.3 INR and a high forecast of 2 520 INR.

SUNPHARMA Lowest Forecast
Wall Street Target
₹1 848.3
0% Downside
SUNPHARMA Average Forecast
Wall Street Target
₹2 193
18% Upside
SUNPHARMA Highest Forecast
Wall Street Target
₹2 520
36% Upside
Lowest Forecast
Price Target
1 848.3 INR
0% Downside
Average Forecast
Price Target
2 193 INR
18% Upside
Highest Forecast
Price Target
2 520 INR
36% Upside
Sun Pharmaceutical Industries Ltd Competitors:
Price Targets

Revenue
Forecast

13% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
13% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 14%.

What are analyst estimates?

Gross Profit
Forecast

13% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
13% / Year
Past Growth
17% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 13%. The projected CAGR for the next 3 years is 17%.

What are analyst estimates?

Operating Income
Forecast

9% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
18% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 9%. The projected CAGR for the next 3 years is 18%.

What are analyst estimates?

Pre-Tax Income
Forecast

10% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
10% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Net Income
Forecast

11% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
11% / Year
Past Growth
19% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 19%.

What are analyst estimates?

Continue SUNPHARMA Research

Summary
SUNPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
SUNPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
SUNPHARMA stock valuation using valuation multiples.
Wall St Estimates
SUNPHARMA price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
SUNPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Sun Pharmaceutical Industries Ltd listings:
BSE • INR
524715
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is SUNPHARMA's stock price target?
Price Target
2 193 INR

According to Wall Street analysts, the average 1-year price target for SUNPHARMA is 2 193 INR with a low forecast of 1 848.3 INR and a high forecast of 2 520 INR.

What is the Revenue forecast for Sun Pharmaceutical Industries Ltd?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Revenue has been 13%. The projected CAGR for the next 3 years is 14%.

What is the Gross Profit forecast for Sun Pharmaceutical Industries Ltd?
Projected CAGR
17%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 13%. The projected CAGR for the next 3 years is 17%.

What is the Operating Income forecast for Sun Pharmaceutical Industries Ltd?
Projected CAGR
18%

Over the last 13 years, the compound annual growth rate for Operating Income has been 9%. The projected CAGR for the next 3 years is 18%.

What is the Pre-Tax Income forecast for Sun Pharmaceutical Industries Ltd?
Projected CAGR
19%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 10%. The projected CAGR for the next 3 years is 19%.

What is the Net Income forecast for Sun Pharmaceutical Industries Ltd?
Projected CAGR
19%

Over the last 13 years, the compound annual growth rate for Net Income has been 11%. The projected CAGR for the next 3 years is 19%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.